Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission

Kana Nagashima; Shohei Kikuchi; Satoshi Iyama; Chisa Fujita; Akari Goto; Hiroto Horiguchi; Masayoshi Kobune

doi:10.1002/ccr3.2688

Clinical Case Reports (Mar 2020)

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission

Kana Nagashima,
Shohei Kikuchi,
Satoshi Iyama,
Chisa Fujita,
Akari Goto,
Hiroto Horiguchi,
Masayoshi Kobune

Affiliations

Kana Nagashima: Department of Hematology Sapporo Medical University School of Medicine Sapporo Japan
Shohei Kikuchi: Department of Hematology Sapporo Medical University School of Medicine Sapporo Japan
Satoshi Iyama: Department of Hematology Sapporo Medical University School of Medicine Sapporo Japan
Chisa Fujita: Department of Hematology Sapporo Medical University School of Medicine Sapporo Japan
Akari Goto: Department of Hematology Sapporo Medical University School of Medicine Sapporo Japan
Hiroto Horiguchi: Department of Hematology Sapporo Medical University School of Medicine Sapporo Japan
Masayoshi Kobune: Department of Hematology Sapporo Medical University School of Medicine Sapporo Japan

DOI: https://doi.org/10.1002/ccr3.2688
Journal volume & issue: Vol. 8, no. 3
pp. 466 – 468

Abstract

Read online

Abstract Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.

Published in Clinical Case Reports

ISSN: 2050-0904 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: https://onlinelibrary.wiley.com/journal/20500904

About the journal

Abstract

Keywords